Investing.com - Ovid Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Ovid Therapeutics announced earnings per share of $-0.170 on revenue of $11.1K. Analysts polled by Investing.com EPS of $-0.227 on revenue of $0.00.
Ovid Therapeutics 's are down 41.36% and is trading at $1.490 , still down 59.73% from its 52 week high of $3.70 set on Monday, November 15, 2021.
Ovid Therapeutics shares gained 3.47% to trade at $1.490 in intra-day trade the report.
Ovid Therapeutics follows other major Healthcare sector earnings this month
Ovid Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar